Jungeon An

Jungeon An currently serves as the Director of Process Development at GeneMedicine, where he plays a pivotal role in advancing innovative gene and viral vector therapies. His leadership is instrumental in driving the company's pipeline forward, particularly through the successful development and optimization of complex bioprocesses. With a strong background in process engineering and biomanufacturing, Jungeon oversees critical projects that span cell line development, upstream and downstream process optimization, and technology transfer, ensuring scalable and compliant manufacturing processes.

One of his notable achievements includes securing Phase I/II IND approval from both the FDA and MFDS for an oncolytic adenovirus therapy, a milestone that underscores his expertise in regulatory strategy and process robustness. His hands-on approach in process development is evident in projects like the insulin glargine cell line optimization, where he led efforts to enhance productivity in E. coli cultures by refining leader sequences—resulting in a significant increase to 20g/L. Additionally, Jungeon has spearheaded upstream process development for botulinum toxin, focusing on improving yield, purity, and process consistency through innovative bioprocessing techniques.

His skill set, encompassing 제약, 생명과학, and 생명공학, reflects a comprehensive understanding of bioprocessing principles, quality assurance, and regulatory compliance. Jungeon’s strategic vision and technical acumen continue to position GeneMedicine at the forefront of gene therapy manufacturing, enabling the company to deliver transformative treatments with efficiency and reliability.